Cargando…

Randomized control trial evaluation of a modified Paleolithic dietary intervention in the treatment of relapsing-remitting multiple sclerosis: a pilot study

BACKGROUND/OBJECTIVE: A Paleolithic diet may improve fatigue and quality of life in progressive multiple sclerosis (MS) patients, but past research has evaluated the effects of this dietary intervention in combination with other treatments such as exercise. Thus, the purpose of this pilot study was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Irish, Amanda K, Erickson, Constance M, Wahls, Terry L, Snetselaar, Linda G, Darling, Warren G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Clinical Trial Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6053098/ https://www.ncbi.nlm.nih.gov/pubmed/30050374 http://dx.doi.org/10.2147/DNND.S116949

Ejemplares similares

Dietary approaches to treat MS-related fatigue: comparing the modified Paleolithic (Wahls Elimination) and low saturated fat (Swank) diets on perceived fatigue in persons with relapsing-remitting multiple sclerosis: study protocol for a randomized controlled trial
por: Wahls, Terry, et al.
Publicado: (2018)

Review of Two Popular Eating Plans within the Multiple Sclerosis Community: Low Saturated Fat and Modified Paleolithic
por: Wahls, Terry L., et al.
Publicado: (2019)

Nutrient Composition Comparison between a Modified Paleolithic Diet for Multiple Sclerosis and the Recommended Healthy U.S.-Style Eating Pattern
por: Chenard, Catherine A., et al.
Publicado: (2019)

Impact of the Swank and Wahls elimination dietary interventions on fatigue and quality of life in relapsing-remitting multiple sclerosis: The WAVES randomized parallel-arm clinical trial
por: Wahls, Terry L, et al.
Publicado: (2021)

Eating Pattern and Nutritional Risks among People with Multiple Sclerosis Following a Modified Paleolithic Diet
por: Titcomb, Tyler J., et al.
Publicado: (2020)

Change in Micronutrient Intake among People with Relapsing-Remitting Multiple Sclerosis Adapting the Swank and Wahls Diets: An Analysis of Weighed Food Records
por: Titcomb, Tyler J., et al.
Publicado: (2021)

Association between improved metabolic risk factors and perceived fatigue during dietary intervention trial in relapsing-remitting multiple sclerosis: A secondary analysis of the WAVES trial
por: Villa, Aneli T., et al.
Publicado: (2023)

Diet-induced changes in functional disability are mediated by fatigue in relapsing-remitting multiple sclerosis: A secondary analysis of the WAVES randomized parallel-arm trial
por: Crippes, Landon J, et al.
Publicado: (2023)

Multimodal intervention improves fatigue and quality of life in subjects with progressive multiple sclerosis: a pilot study
por: Bisht, Babita, et al.
Publicado: (2015)

Disease-modifying therapies in relapsing–remitting multiple sclerosis
por: González-Andrade, Fabricio, et al.
Publicado: (2010)

Short-term interval aerobic exercise training does not improve memory functioning in relapsing-remitting multiple sclerosis—a randomized controlled trial
por: Baquet, Lisa, et al.
Publicado: (2018)

Nutrient Composition Comparison between the Low Saturated Fat Swank Diet for Multiple Sclerosis and Healthy U.S.-Style Eating Pattern
por: Chenard, Catherine A., et al.
Publicado: (2019)

Balance Changes in Patients With Relapsing-Remitting Multiple Sclerosis: A Pilot Study Comparing the Dynamics of the Relapse and Remitting Phases
por: Findling, Oliver, et al.
Publicado: (2018)

When to Initiate Disease-Modifying Drugs for Relapsing Remitting Multiple Sclerosis in Adults?
por: Alkhawajah, Mona, et al.
Publicado: (2011)

Brain Atrophy as an Outcome of Disease-Modifying Therapy for Remitting-Relapsing Multiple Sclerosis
por: Chylińska, Magdalena, et al.
Publicado: (2023)

Association of multiple sclerosis with risk of mortality among a nationally representative sample of adults in the United States
por: Titcomb, Tyler J., et al.
Publicado: (2022)

Postural Control in Relapsing-Remitting Multiple Sclerosis
por: Cusin, Flavia Salvaterra, et al.
Publicado: (2022)

Cost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in Iran
por: Imani, Ali, et al.
Publicado: (2012)

Use of Disease-Modifying Therapies in Pediatric Relapsing-Remitting Multiple Sclerosis in the United Kingdom
por: Abdel-mannan, Omar A., et al.
Publicado: (2021)

Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
por: Tenorio-Laranga, Jofre, et al.
Publicado: (2010)

Varicella Zoster Virus and Relapsing Remitting Multiple Sclerosis
por: Sotelo, Julio, et al.
Publicado: (2011)

Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis
por: Chan, Andrew, et al.
Publicado: (2016)

An Overview of Therapeutic Options in Relapsing-remitting Multiple Sclerosis
por: Saleem, Sidra, et al.
Publicado: (2019)

Abnormal multisensory integration in relapsing–remitting multiple sclerosis
por: Giurgola, Serena, et al.
Publicado: (2022)

The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A Narrative Review
por: Biolato, Marco, et al.
Publicado: (2021)

Comparison of Pharmacological Therapies in Relapse Rates in Patients With Relapsing-Remitting Multiple Sclerosis
por: Etta, Indu, et al.
Publicado: (2023)

Relapse recovery in relapsing–remitting multiple sclerosis: An analysis of the CombiRx dataset
por: Koch, Marcus W, et al.
Publicado: (2023)

Effects of a multimodal intervention on gait and balance of subjects with progressive multiple sclerosis: a prospective longitudinal pilot study
por: Bisht, Babita, et al.
Publicado: (2017)

Longitudinal cortical network reorganization in early relapsing–remitting multiple sclerosis
por: Fleischer, Vinzenz, et al.
Publicado: (2019)

Gut microbiota in forty cases of egyptian relapsing remitting multiple sclerosis
por: Elgendy, Sherein G., et al.
Publicado: (2021)

Natalizumab: A new treatment for relapsing remitting multiple sclerosis
por: Hutchinson, Michael
Publicado: (2007)

Alemtuzumab: evidence for its potential in relapsing—remitting multiple sclerosis
por: Brown, JWL, et al.
Publicado: (2013)

Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis
por: Romme Christensen, Jeppe, et al.
Publicado: (2012)

Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
por: Lugaresi, Alessandra, et al.
Publicado: (2013)

Defective structural RNA processing in relapsing-remitting multiple sclerosis
por: Spurlock, Charles F, et al.
Publicado: (2015)

Thalamic–hippocampal–prefrontal disruption in relapsing–remitting multiple sclerosis
por: Kern, Kyle C., et al.
Publicado: (2014)

Natalizumab is Effective for the Treatment of Relapsing-remitting Tumefactive Multiple Sclerosis
por: Nakamura, Masataka, et al.
Publicado: (2017)

Sexual dysfunction in female patients with relapsing‐remitting multiple sclerosis
por: Bartnik, Pawel, et al.
Publicado: (2017)

Cerebellar Information Processing in Relapsing-Remitting Multiple Sclerosis (RRMS)
por: Lesage, E., et al.
Publicado: (2010)

Treatment with Rituximab in the Acute Phase of Relapsing Remitting Multiple Sclerosis
por: Shima, Ayano, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0h25toa9276qunhcv0kq993tdb